Jonathan Wolleben
Stock Analyst at Citizens JMP
(4.90)
# 269
Out of 4,690 analysts
746
Total ratings
54.2%
Success rate
23.8%
Average return
Main Sectors:
Stocks Rated by Jonathan Wolleben
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SION Sionna Therapeutics | Downgraded: Hold | n/a | $5.87 | - | 2 | Aug 10, 2026 | |
| GPCR Structure Therapeutics | Maintained: Buy | $113 → $110 | $47.37 | +132.21% | 26 | Aug 7, 2026 | |
| MIRM Mirum Pharmaceuticals | Maintained: Buy | $146 → $137 | $97.46 | +40.57% | 33 | Aug 6, 2026 | |
| BMEA Biomea Fusion | Maintained: Buy | $9 → $7 | $1.73 | +304.62% | 2 | Aug 6, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintained: Buy | $152 → $160 | $107.17 | +49.30% | 22 | Aug 5, 2026 | |
| ANNX Annexon | Initiated Coverage: Sell | $3 | $4.97 | -39.64% | 1 | Jul 21, 2026 | |
| MDGL Madrigal Pharmaceuticals | Maintained: Buy | $745 → $739 | $533.76 | +38.45% | 62 | Jul 17, 2026 | |
| PTGX Protagonist Therapeutics | Maintained: Buy | $137 → $165 | $144.33 | +14.32% | 37 | Jul 17, 2026 | |
| CRNX Crinetics Pharmaceuticals | Downgraded: Hold | n/a | $84.84 | - | 49 | Jul 7, 2026 | |
| DBVT DBV Technologies | Maintained: Buy | $55 | $13.54 | +306.20% | 45 | Jun 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $35 → $12 | $10.55 | +13.74% | 21 | May 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $14 → $11 | $3.11 | +253.70% | 81 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $170 → $150 | $60.78 | +146.79% | 28 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 → $11 | $3.69 | +198.10% | 2 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $26 → $25 | $4.03 | +520.35% | 3 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $52 → $74 | $35.32 | +109.51% | 34 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $61 → $86 | $63.00 | +36.51% | 4 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $25 → $28 | $9.82 | +185.13% | 49 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $2.29 | +249.34% | 42 | Mar 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $10.36 | - | 63 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $33.75 | - | 5 | Jan 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $8 → $11 | $5.26 | +109.13% | 17 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $4.01 | +348.88% | 41 | Oct 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $15 → $4 | $1.78 | +125.35% | 7 | Oct 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $19 | $7.40 | n/a | 27 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $16.81 | n/a | 42 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $24 | $28.03 | n/a | 1 | May 12, 2023 |
Sionna Therapeutics
Aug 10, 2026
Downgraded: Hold
Price Target: n/a
Current: $5.87
Upside: -
Structure Therapeutics
Aug 7, 2026
Maintained: Buy
Price Target: $113 → $110
Current: $47.37
Upside: +132.21%
Mirum Pharmaceuticals
Aug 6, 2026
Maintained: Buy
Price Target: $146 → $137
Current: $97.46
Upside: +40.57%
Biomea Fusion
Aug 6, 2026
Maintained: Buy
Price Target: $9 → $7
Current: $1.73
Upside: +304.62%
Rhythm Pharmaceuticals
Aug 5, 2026
Maintained: Buy
Price Target: $152 → $160
Current: $107.17
Upside: +49.30%
Annexon
Jul 21, 2026
Initiated Coverage: Sell
Price Target: $3
Current: $4.97
Upside: -39.64%
Madrigal Pharmaceuticals
Jul 17, 2026
Maintained: Buy
Price Target: $745 → $739
Current: $533.76
Upside: +38.45%
Protagonist Therapeutics
Jul 17, 2026
Maintained: Buy
Price Target: $137 → $165
Current: $144.33
Upside: +14.32%
Crinetics Pharmaceuticals
Jul 7, 2026
Downgraded: Hold
Price Target: n/a
Current: $84.84
Upside: -
DBV Technologies
Jun 30, 2026
Maintained: Buy
Price Target: $55
Current: $13.54
Upside: +306.20%
May 19, 2026
Maintained: Buy
Price Target: $35 → $12
Current: $10.55
Upside: +13.74%
May 14, 2026
Maintained: Buy
Price Target: $14 → $11
Current: $3.11
Upside: +253.70%
May 14, 2026
Maintained: Buy
Price Target: $170 → $150
Current: $60.78
Upside: +146.79%
May 13, 2026
Maintained: Buy
Price Target: $12 → $11
Current: $3.69
Upside: +198.10%
May 13, 2026
Maintained: Buy
Price Target: $26 → $25
Current: $4.03
Upside: +520.35%
May 13, 2026
Maintained: Buy
Price Target: $52 → $74
Current: $35.32
Upside: +109.51%
May 12, 2026
Maintained: Buy
Price Target: $61 → $86
Current: $63.00
Upside: +36.51%
May 7, 2026
Maintained: Buy
Price Target: $25 → $28
Current: $9.82
Upside: +185.13%
Mar 12, 2026
Reiterated: Buy
Price Target: $8
Current: $2.29
Upside: +249.34%
Feb 17, 2026
Maintained: Buy
Price Target: n/a
Current: $10.36
Upside: -
Jan 29, 2026
Downgraded: Hold
Price Target: n/a
Current: $33.75
Upside: -
Oct 23, 2025
Maintained: Buy
Price Target: $8 → $11
Current: $5.26
Upside: +109.13%
Oct 6, 2025
Reiterated: Buy
Price Target: $18
Current: $4.01
Upside: +348.88%
Oct 6, 2025
Maintained: Buy
Price Target: $15 → $4
Current: $1.78
Upside: +125.35%
May 23, 2025
Reiterated: Buy
Price Target: $19
Current: $7.40
Upside: n/a
Apr 23, 2025
Reiterated: Hold
Price Target: n/a
Current: $16.81
Upside: n/a
May 12, 2023
Maintained: Buy
Price Target: $24
Current: $28.03
Upside: n/a